Newsbenzinga
Zymeworks To Acquire Theravance Biopharma At $17 Per Share For Total Cash Consideration Of $929M
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…